PYY3-36 potently reduces appetite through Y2 receptor-mediated hypothalamic signaling, but clinical development faces challenges including nausea at therapeutic doses and limited duration of effect.
Key findingPYY3-36 reduces food intake through peripheral Y2 receptor-mediated hypothalamic appetite suppression, with clinical development challenges including
What the researchers found
PYY3-36 reduces food intake through peripheral Y2 receptor-mediated hypothalamic appetite suppression, with clinical development challenges including dose-limiting nausea, route-dependent efficacy, and need for sustained-release formulations.
Why it matters
Relevant for neuropeptides, weight-loss.
How the study worked
review study on neuropeptides, weight-loss.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2005.
The bigger picture
Advances peptide/biomarker research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Peptide YY: a potential therapy for obesity.
Current drug targets, 6(2), 171-9
Citation
Renshaw, D; Batterham, R L. (2005). Peptide YY: a potential therapy for obesity.. Current drug targets, 6(2), 171-9.